Type 1 diabetes is the most common form of diabetes in children and adolescents. Currently, people with type 1 diabetes rely on insulin shots based on constant blood sugar checks, diet and exercise. There is a need for more treatment options for people with type 1 diabetes.
The T1GER research study will assess a study drug (Golimumab) for the treatment of type 1 diabetes in children and adolescents.
About the Study
The T1GER research study will test the safety and effectiveness of the study drug in children and young adults with newly diagnosed type 1 diabetes.
Scientists at Pennington Biomedical will assess if the study drug can preserve beta-cell function in the body. The main function of a beta cell is to produce insulin which makes levels of glucose in the blood normal. In people with type 1 diabetes, these cells are attacked and destroyed by the immune system.
- 1 screening visit
- 11 treatment visits to the Pennington Biomedical outpatient clinic
- 2 follow up visits
- Health measurements (blood pressure, pulse, height, weight, etc.)
- Physical examination
- Meal test (to test metabolism)
- Blood tests
Number of Visits:
- Be 6 to 21 years of age.
- Be diagnosed with type 1 diabetes within 100 days of study participation.
To qualify, participants in this study should:
Study DurationParticipation in this study will last approximately 2 years.
CompensationFinancial compensation will be provided to study participants.
Study ContactTo see if you or your child qualifies for this research study, you or a parent or guardian must complete the online screening form below. You may also call 225-763-3000 or email firstname.lastname@example.org
If you think you may be eligible, please click the button below to screen online.GET STARTED
Please do not fill out this questionnaire for anyone other than yourself unless you are their legal guardian.
If you know someone who may be interested please direct them to the site or have them call us directly at 225-763-3000.